Immunotherapy for Various Types of Cancer
Immune Profiling for Cancer Immunotherapy Response
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 1,500 (estimated)
- Sponsor
- Dartmouth-Hitchcock Medical Center · Other
This trial is looking for cancer patients who are receiving or will receive FDA-approved immunotherapy treatment. It involves assessing how the immune system's response may predict how well the treatment works.
You may be able to join if
- I have cancer
- I am receiving or will receive FDA-approved immunotherapy
- I have had other types of therapy before
You may not be able to join if
- I am pregnant or breastfeeding
- I am incarcerated
- I have difficulty making decisions
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityIn patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.
Loading trial locations…